Johnson & Johnson

BRSE:000943981 Stock Report

Market Cap: CHF 338.2b

Johnson & Johnson Valuation

Is 000943981 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 000943981 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 322.03
Fair Value
56.0% undervalued intrinsic discount
21
Number of Analysts

Below Fair Value: 000943981 (CHF141.72) is trading below our estimate of fair value (CHF322.03)

Significantly Below Fair Value: 000943981 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 000943981?

Key metric: As 000943981 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 000943981. This is calculated by dividing 000943981's market cap by their current earnings.
What is 000943981's PE Ratio?
PE Ratio26.7x
EarningsUS$14.07b
Market CapUS$375.95b

Price to Earnings Ratio vs Peers

How does 000943981's PE Ratio compare to its peers?

The above table shows the PE ratio for 000943981 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.2x
ROG Roche Holding
28.3x14.6%CHF 236.6b
NOVN Novartis
17.5x7.0%CHF 188.4b
DESN Dottikon ES Holding
39.2xn/aCHF 3.0b
COPN Cosmo Pharmaceuticals
15.7x21.5%CHF 1.0b
000943981 Johnson & Johnson
26.7x8.4%CHF 375.9b

Price-To-Earnings vs Peers: 000943981 is expensive based on its Price-To-Earnings Ratio (26.7x) compared to the peer average (25.2x).

Price to Earnings Ratio vs Industry

How does 000943981's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
000943981 26.7xIndustry Avg. 22.6xNo. of Companies9PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 000943981 is expensive based on its Price-To-Earnings Ratio (26.7x) compared to the European Pharmaceuticals industry average (22.6x).

Price to Earnings Ratio vs Fair Ratio

What is 000943981's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

000943981 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.7x
Fair PE Ratio40.2x

Price-To-Earnings vs Fair Ratio: 000943981 is good value based on its Price-To-Earnings Ratio (26.7x) compared to the estimated Fair Price-To-Earnings Ratio (40.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 000943981 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 141.72
CHF 153.71
+8.5%
6.8%CHF 173.17CHF 136.72n/a21
Feb ’26CHF 139.06
CHF 152.31
+9.5%
6.8%CHF 171.80CHF 135.63n/a21
Jan ’26CHF 131.02
CHF 155.50
+18.7%
7.2%CHF 191.83CHF 138.29n/a23
Dec ’25CHF 138.81
CHF 154.47
+11.3%
7.3%CHF 189.90CHF 136.91n/a23
Nov ’25CHF 140.05
CHF 150.94
+7.8%
7.3%CHF 186.21CHF 134.24n/a22
Oct ’25CHF 135.98
CHF 145.35
+6.9%
8.0%CHF 182.40CHF 127.26n/a22
Sep ’25CHF 139.57
CHF 145.43
+4.2%
8.0%CHF 182.80CHF 127.53n/a22
Aug ’25CHF 141.95
CHF 152.16
+7.2%
8.0%CHF 191.68CHF 133.73n/a22
Jul ’25CHF 131.55
CHF 153.39
+16.6%
7.7%CHF 192.05CHF 138.46n/a22
Jun ’25CHF 132.38
CHF 155.34
+17.3%
7.8%CHF 194.24CHF 140.03n/a22
May ’25CHF 134.07
CHF 158.82
+18.5%
7.8%CHF 197.62CHF 142.47n/a21
Apr ’25CHF 143.01
CHF 158.59
+10.9%
7.1%CHF 194.39CHF 144.66n/a21
Mar ’25CHF 142.26
CHF 153.27
+7.7%
7.5%CHF 189.12CHF 138.10n/a21
Feb ’25CHF 137.42
CHF 149.71
+8.9%
7.4%CHF 184.41CHF 134.66CHF 139.0622
Jan ’25CHF 131.43
CHF 151.63
+15.4%
7.2%CHF 186.48CHF 136.17CHF 131.0222
Dec ’24CHF 136.56
CHF 151.74
+11.1%
7.4%CHF 186.91CHF 134.75CHF 138.8122
Nov ’24CHF 135.18
CHF 157.32
+16.4%
6.9%CHF 192.03CHF 140.23CHF 140.0522
Oct ’24CHF 143.12
CHF 161.39
+12.8%
6.5%CHF 192.97CHF 141.81CHF 135.9821
Sep ’24CHF 143.01
CHF 160.36
+12.1%
6.0%CHF 190.48CHF 145.30CHF 139.5721
Aug ’24CHF 150.56
CHF 159.03
+5.6%
6.1%CHF 187.50CHF 143.03CHF 141.9520
Jul ’24n/a
CHF 163.23
0%
6.9%CHF 195.84CHF 146.65CHF 131.5520
Jun ’24CHF 140.03
CHF 163.23
+16.6%
6.9%CHF 195.84CHF 146.65CHF 132.3820
May ’24n/a
CHF 159.49
0%
7.1%CHF 191.79CHF 143.62CHF 134.0719
Apr ’24CHF 140.96
CHF 163.48
+16.0%
7.2%CHF 197.56CHF 147.94CHF 143.0121
Mar ’24CHF 146.48
CHF 168.47
+15.0%
7.0%CHF 202.08CHF 151.32CHF 142.2621
Feb ’24CHF 150.35
CHF 167.38
+11.3%
6.5%CHF 198.93CHF 151.74CHF 137.4220
Analyst Price Target
Consensus Narrative from 21 Analysts
CHF 153.06
Fair Value
7.4% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/15 23:33
End of Day Share Price 2025/02/14 00:00
Earnings2024/12/29
Annual Earnings2024/12/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Johnson & Johnson is covered by 56 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Charles ButlerBarclays
Matt MiksicBarclays